Corbus Pharmaceuticals Holdings, Inc.
CRBP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $882 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $600 | $0 | $1,488 | $1,639 |
| Gross Profit | -$600 | $0 | -$1,488 | -$758 |
| % Margin | – | – | – | -85.9% |
| R&D Expenses | $32,222 | $31,168 | $16,137 | $36,445 |
| G&A Expenses | $16,499 | $13,910 | $18,699 | $20,425 |
| SG&A Expenses | $16,499 | $13,910 | $18,699 | $20,425 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$600 | $0 | -$1,488 | -$1,639 |
| Operating Expenses | $48,121 | $45,078 | $33,348 | $55,231 |
| Operating Income | -$48,721 | -$45,078 | -$34,835 | -$55,989 |
| % Margin | – | – | – | -6,350.1% |
| Other Income/Exp. Net | $8,512 | $474 | -$7,511 | $10,349 |
| Pre-Tax Income | -$40,209 | -$44,604 | -$42,347 | -$45,640 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$40,209 | -$44,604 | -$55,833 | -$45,553 |
| % Margin | – | – | – | -5,166.4% |
| EPS | -3.68 | -10.31 | -10.15 | -11.11 |
| % Growth | 64.3% | -1.6% | 8.6% | – |
| EPS Diluted | -3.68 | -10.31 | -10.15 | -11.11 |
| Weighted Avg Shares Out | 10,915 | 4,327 | 4,171 | 4,100 |
| Weighted Avg Shares Out Dil | 10,915 | 4,328 | 4,171 | 4,100 |
| Supplemental Information | – | – | – | – |
| Interest Income | $6,311 | $0 | $0 | $0 |
| Interest Expense | $1,872 | $2,924 | $2,132 | $1,830 |
| Depreciation & Amortization | $600 | $641 | $1,488 | $1,639 |
| EBITDA | -$37,737 | -$40,105 | -$38,727 | -$54,350 |
| % Margin | – | – | – | -6,164.2% |